Asthma severity can be affected by multiple inflammatory pathways, which make it challenging to treat with a “one size fits all” approach. This is why researchers started pursuing precision medicine for asthma – distinguishing disease types based on specific biological signs (called biomarkers) and matching treatments to the patient’s asthma type.

Trustworthy Artificial Intelligence for Personalised Risk Assessment, or AI4HF, is a 4-year project funded by the European Union’s Horizon Europe Framework 

AI4HF aims to co-design, develop and evaluate the first trustworthy artificial intelligence (AI) tool for personalising the care and management of patients with heart failure. 

The project brings together patients, clinicians and other stakeholders from Europe, South America and Africa with regular workshops to allow input from all 

The workshops have produced many ideas for refining AI for heart failure treatment, including increasing health and digital literacy, personalised recommendations on improving lifestyle, and social components such as involvement of carers. A new round of workshops is ongoing